Dr. Whelan is a subject matter expert in cancer biomarker detection, and has made numerous contributions to the understanding of the structure, functions, and clinical utility of CA125, the gold standard ovarian cancer biomarker. Her research work builds on fundamental molecular level characterization of proteins that are elevated during the development of ovarian cancer and can therefore serve as indicators of the disease’s progression and recurrence. Using innovative multiomics techniques, Dr. Whelan and her research group have developed new ways to detect CA125 and have identified limitations in the performance of the CA125 assay that her group is currently working to address. She has presented nationally on her work on CA125. Dr. Whelan is committed to educating and mentoring the next generation of scholars and scientists and has pursued this educational mission alongside her research work at Oberlin College, the University of Notre Dame, and the University of Kansas.
Dr. Whelan is a subject matter expert in cancer biomarker detection, and has made numerous contributions to the understanding of the structure, functions, and clinical utility of CA125, the gold standard ovarian cancer biomarker. Her research work builds on fundamental molecular level characterization of proteins that are elevated during the development of ovarian cancer and can therefore serve as indicators of the disease’s progression and recurrence. Using innovative multiomics techniques, Dr. Whelan and her research group have developed new ways to detect CA125 and have identified limitations in the performance of the CA125 assay that her group is currently working to address. She has presented nationally on her work on CA125. Dr. Whelan is committed to educating and mentoring the next generation of scholars and scientists and has pursued this educational mission alongside her research work at Oberlin College, the University of Notre Dame, and the University of Kansas.